New research has shown aggressive autologous haematopoietic stem cell transplantation (AHSCT) can halt relapses for people with highly active, relapsing MS This trial involved 24 people and used high intensity chemotherapy prior to stem cell transplantation, with the aim of completely eliminating and then resetting the immune system.
Research published in the journal Neuron has identified a gene associated with the development of progressive MS. Researchers from Canada found a particular difference in this gene was associated with an increased risk of developing rapidly progressive forms of MS.
The European Medicines Agency (EMA) has recommended daclizumab, known as Zinbryta, be licensed to treat people with relapsing forms of MS. The National Institute for Health and Care Excellence (NICE) is now deciding whether to make this treatment available on the NHS in England and Wales.
News in the of this week's budget announcement has been dominated by the Government’s plans to make cuts to Personal Independence Payment (PIP).
The MS Society has been consistently speaking out about the devastating impact these changes could have on people with MS, and now we're calling for this issue to be urgently debated in Parliament.